IBRX

ImmunityBio Inc

Jun 12 • 04:00PM ET

7.10

-0.10 -1.39 %

Healthcare • Biotechnology • USA • Mid • NASD

Peers: BNTX MRNA BMRN INCY ARWR IONS ALNY REGN VRTX BIIB

| Held by: XBI VTI VB IWM VBK VXF IBB IWO VTWO SCHA

Index	RUT	P/E	-	EPS (ttm)	-0.85	Insider Own	62.91%	Shs Outstand	1.05B	Perf Week	2.60%
Market Cap	7.44B	Forward P/E	-	EPS next Y	-0.16	Insider Trans	-0.08%	Shs Float	388.46M	Perf Month	-12.88%
Enterprise Value	8.18B	PEG	-	EPS next Q	-0.09	Inst Own	17.23%	Short Float	34.02%	Perf Quarter	-15.38%
Income	-854.53M	P/S	52.75	EPS this Y	-123.68%	Inst Trans	1.88%	Short Ratio	7.73	Perf Half Y	208.70%
Sales	140.98M	P/B	-	EPS next Y	81.57%	ROA	-179.83%	Short Interest	132.14M	Perf YTD	258.59%
Book/sh	-0.83	P/C	19.52	EPS next 5Y	-	ROE	-	52W High	12.43 -42.88%	Perf Year	122.57%
Cash/sh	0.36	P/FCF	-	EPS past 3/5Y	28.42% 15.60%	ROIC	-347.32%	52W Low	1.95 264.10%	Perf 3Y	148.25%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	678.62% 299.74%	Gross Margin	87.93%	Volatility	5.49% 6.43%	Perf 5Y	-53.26%
Dividend TTM	-	EV/Sales	58.03	EPS Y/Y TTM	-54.81%	Oper. Margin	-185.41%	ATR (14)	0.49	Perf 10Y	5.97%
Dividend Ex-Date	-	Quick Ratio	6.66	Sales Y/Y TTM	351.53%	Profit Margin	-606.15%	RSI (14)	44.24	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	6.67	EPS Q/Q	-305.39%	SMA20	-4.92%	Beta	0.12	Target Price	13.00
Payout	-	Debt/Eq	-	Sales Q/Q	167.64%	SMA50	-5.98%	Rel Volume	0.51	Prev Close	7.20
Employees	691	LT Debt/Eq	-	Earnings	May 07 BMO	SMA200	40.84%	Avg Volume	17.09M	Price	7.10
IPO	Jul 28, 2015	Option/Short	Yes / Yes	EPS/Sales Surpr.	-779.43% 2.64%	Trades		Volume	8,768,784	Change	-1.39%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-12-26	Resumed	BTIG Research	Buy	$13
May-20-25	Upgrade	Piper Sandler	Neutral → Overweight	$5
Mar-06-25	Initiated	H.C. Wainwright	Buy	$8
Jan-10-25	Initiated	BTIG Research	Buy	$6
May-12-23	Downgrade	Piper Sandler	Overweight → Neutral	$10 → $4
Aug-03-22	Initiated	Jefferies	Buy	$8

Jun-01-26 01:51PM	ImmunityBio Presents New Clinical and Comparative Data Across Lung and Bladder Cancer at ASCO 2026 (Business Wire)
May-29-26 09:00AM	The $13 Million Company Teaching the Immune System to Hunt Cancer (PR Newswire)
May-22-26 08:27AM	IBRX Says ANKTIVA Delivers Up To $314K Cost Advantage Over J&J's TAR-200 Everything To Know About ImmunityBios Findings (Stocktwits) -6.72%
07:30AM	ImmunityBio Presents Health Economic Analysis at ISPOR 2026 Showing ANKTIVA Plus BCG Delivers Lower Cost per Sustained Complete Response Versus TAR-200 in BCG-Unresponsive NMIBC CIS (Business Wire)
07:30AM	ImmunityBio Highlights Patient Survey Data at ISPOR 2026 Showing Majority of UK Adults Living with NMIBC Favor Bladder Preservation (Business Wire)
09:00AM	Loading…
May-21-26 09:00AM	ImmunityBio (IBRX) Facing Lawsuit After FDA Flags Misleading Cancer Claims, Shares Plunge 21%, $2B Market Cap Lost -- HBSS (PR Newswire)
May-19-26 08:30PM	ImmunityBio Announces FDA Acceptance of Supplemental BLA for ANKTIVA Plus BCG in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer with Papillary Disease; PDUFA Date Set for January 6, 2027 (Business Wire)
09:00AM	Three TriKE Candidates In Clinic As NK Cell Engager Field Reorganizes (PR Newswire)
07:30AM	ImmunityBio Presents Favorable Comparative Effectiveness Data in Complete Response Rates of NAI + BCG Versus Nadofaragene and TAR-200 at AUA 2026 (Business Wire)
May-18-26 10:35AM	ImmunityBio Shares Rise After Securing Five New U.S. Patents for Bladder Cancer Therapy (IBRX) (InvestorsHub)
07:30AM	ImmunityBio Announces Comprehensive U.S. Patents Covering Combination of ANKTIVA with BCG for Cancer Treatment, with Terms Through 2035 (Business Wire)
May-16-26 01:35PM	ImmunityBio Signs Exclusive U.S. Agreement with Japan BCG Laboratory for the Tokyo Strain of BCG to Enhance BCG Supply in the United States (Business Wire)
May-07-26 07:45AM	ImmunityBio: Q1 Earnings Snapshot (Associated Press) -7.40%
07:30AM	ImmunityBio Reports Record Q1 2026 Results: Net Product Revenue Increased Nearly 2.7x Year-Over-Year to $44 Million in Q1 2026 Expanding on the 2025 Full Year 700% Year-Over-Year Revenue Growth; Cash and Marketable Securities Total $381 Million (Business Wire)
May-05-26 07:30AM	ImmunityBio to Present New Comparative Data, Scientific Advances in Non-Muscle Invasive Bladder Cancer CIS and an Update on BCG Naive Registrational Trial at American Urological Association Annual Meeting (Business Wire)
09:00AM	Loading…
Apr-30-26 09:00AM	IBRX Lawsuit Alleges Company Allegedly Violated Drug Promotion Laws - ImmunityBio Investors Face Losses Following Company Allegedly Violated Drug Promotion Laws: Hagens Berman (PR Newswire)
09:00AM	IBRX Lawsuit Alleges Chairman Allegedly Overstated Drug Capabilities - ImmunityBio Investors Face Losses Following Chairman Allegedly Overstated Drug Capabilities: SueWallSt (PR Newswire)
Apr-23-26 09:00AM	IBRX Lawsuit Alleges Company Allegedly Violated Drug Promotion Laws - ImmunityBio Investors Face Losses Following Company Allegedly Violated Drug Promotion Laws: SueWallSt (PR Newswire)
Apr-21-26 07:30AM	ImmunityBio Announces ANKTIVA Is Now Available in Saudi Arabia for Bladder and Lung Cancer Patients; Market Entry Achieved Within Two Months of MENA Partnership (Business Wire)
Apr-16-26 09:00AM	IBRX Lawsuit Alleges Chairman Allegedly Concealed Drug Limitation Risks - ImmunityBio Investors Face Losses Following Chairman Allegedly Concealed Drug Limitation Risks: SueWallSt (PR Newswire) -6.81%
Apr-09-26 07:30AM	ImmunityBio Reports Net Product Revenue Increased Nearly 2.7 Times Year-Over-Year to Record $44 Million in Q1 2026 and $381 Million in Cash and Marketable Securities (Business Wire) +7.16%
Apr-06-26 07:30AM	ImmunityBio Addresses FDA Correspondence and Reaffirms Commitment to Advertising Compliance (Business Wire)
Apr-03-26 01:48AM	ImmunityBio, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - IBRX (PR Newswire)
Apr-01-26 04:07PM	ImmunityBio (IBRX) Sued After FDA Flags Misleading Cancer Claims, Shares Plunge 21%, $2B Market Cap Lost -- Hagens Berman (PR Newswire) -6.91%
Mar-31-26 07:30AM	ImmunityBio Strengthens Balance Sheet with $100 Million of Financing Transactions Including $75 Million of Non-Dilutive Financing to Support Global Expansion and Advancement of Broader Immunotherapy Pipeline (Business Wire) +15.17%
Mar-29-26 07:30AM	ImmunityBio, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights IBRX (Business Wire)
Mar-27-26 09:15AM	Scalable Biotech Manufacturing Unlocks a $14B Market (PR Newswire)
Mar-26-26 07:30AM	ImmunityBio Confirms Statistical Power in Pivotal Randomized BCG-Naive NMIBC Trial to Detect Clinically Meaningful Differences Between ANKTIVA Plus BCG Versus BCG Alone; Supplemental BLA Submission on Track for 2026 (Business Wire) -8.55%
Mar-24-26 03:45PM	ImmunityBio Stock Tumbles 25% on FDA Warning. No, Its Drug Can't 'Treat All Cancers.' (Barrons.com) -21.12%
02:03PM	FDA flags misleading claims for cancer drug by biotech billionaire Patrick Soon-Shiong (Associated Press Finance)
12:56PM	Loading…
12:56PM	ImmunityBio Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses (Newsfile)
Mar-23-26 06:41AM	ImmunityBio receives Macau approval for Anktiva combo therapy (Pharmaceutical Business Review) +10.98%
Mar-20-26 01:08PM	ImmunityBio Announces Approval in Macau SAR, China for ANKTIVA in BCG-Unresponsive NMIBC with CIS ± Papillary Tumors (Business Wire)
Mar-17-26 08:00PM	The Stubborn Billionaire Behind the L.A. Times's Revamp (The Wall Street Journal)
07:30AM	ImmunityBio Announces NCCN Clinical Practice Guidelines in Oncology Have Been Updated to Include ANKTIVA Plus BCG for Patients With BCG-Unresponsive NMIBC With Papillary-Only Disease (Business Wire)
Mar-13-26 07:30AM	ImmunityBio Achieves Milestone with Large-Scale NK Cell Production and Cryopreservation from Over 60 Healthy and Cancer Donors (Business Wire) +7.29%
Mar-10-26 03:32AM	Piper Sandler Keeps an Overweight Rating on ImmunityBio, Inc. (IBRX) (Insider Monkey) -5.21%
Mar-09-26 11:03AM	ImmunityBio Announces FDA Resubmission For Expanded Use Of Lead Drug (Benzinga)
07:30AM	ImmunityBio Announces Resubmission of Supplemental BLA to the FDA for ANKTIVA Plus BCG in BCG-Unresponsive NMIBC with Papillary Disease Following Agency Review of Additional Data (PR Newswire)
Mar-06-26 10:20AM	H.C. Wainwright Raised Its Price Target on ImmunityBio, Inc. (IBRX) to $15 from $10 and Maintains a Buy Rating (Insider Monkey)
Mar-04-26 02:30AM	ImmunityBio, Inc. (IBRX) Price Target Raised After Strong ANKTIVA Launch (Insider Monkey) -10.00%
Mar-03-26 07:02PM	ImmunityBio Q4 Earnings Call Highlights (MarketBeat)
08:30AM	ImmunityBio, Inc. Q4 2025 Earnings Call Summary (Moby)
Feb-27-26 07:30AM	ImmunityBio to Provide a Business Update and Review Financial Results for FY 2025 on Tuesday, March 3, 2026 (Business Wire)
Feb-26-26 11:22PM	IBRX Stock Ignites Retail Frenzy Ahead Of Founders Prime-Time TV Blitz Traders Bets On Saudi Funding And Trump Tailwinds (New feeds test provider finance)
08:57AM	ImmunityBio Investors Rally Behind Cancer Trial Milestone (Benzinga)
07:30AM	ImmunityBio Completes Enrollment in Pivotal Randomized Trial Evaluating ANKTIVA Plus BCG Versus BCG Alone in BCG-Nave Non-Muscle Invasive Bladder Cancer Carcinoma In Situ (Business Wire)
02:08AM	ImmunityBio (IBRX) Loses 17% to Profit-Taking After Intra-Day High (Insider Monkey)
Feb-25-26 01:02PM	ImmunityBio Supersedes Expectations With Fivefold Revenue Increase (Benzinga) -17.40%
09:09AM	ImmunityBio's 471% Stock Rally Could Enter Next Round If Shorts Capitulate (Benzinga)
09:00AM	Immuno-Oncology Investments Accelerate as Pipeline Catalysts Multiply in 2026 (PR Newswire)
06:19AM	ImmunityBio (IBRX) Reports 700% Revenue Surge Driven by Rapid ANKTIVA Adoption (Insider Monkey)
01:44AM	ImmunityBio (IBRX) Skyrockets as Anktiva Propels 671% Revenue Jump (Insider Monkey)
Feb-23-26 04:15PM	ImmunityBio Founder Dr. Patrick Soon-Shiong to Speak at Milken Institute and Richard Nixon Foundation "Cancer 2035: A Roadmap for the Future" Summit (Business Wire) +12.99% +17.50%
12:34PM	ImmunityBio Explodes To Near 52-Week High As Bladder Cancer Drug Anktiva Drives Massive 700% Revenue Growth (Benzinga)
10:35AM	ImmunityBio (IBRX) Reports Q4 Loss, Beats Revenue Estimates (Zacks)
09:40AM	ImmunityBio: Q4 Earnings Snapshot (Associated Press Finance)
07:00AM	ImmunityBio Reports 700% Year-Over-Year Revenue Growth, Expanded ANKTIVA Approvals in Lung Cancer and Global Commercial Partnerships in 33 Countries with Label Expansion Plans Globally (Business Wire)
Feb-20-26 09:05AM	ImmunityBio Taps 85-Person Sales Team to Launch Its Bladder Cancer Drug In European Countries (Benzinga)
08:30AM	ImmunityBio Partners with Biopharma and Cigalah Healthcare to Launch ANKTIVA in Saudi Arabia for Bladder and Lung Cancer Patients (Business Wire)
Feb-19-26 11:37AM	ImmunityBio Holds Golden Cross As Stock Trades 170% Above 200-Day Average (Benzinga)
09:00AM	ImmunityBio Expands Access to ANKTIVA in EU with New Distribution Partnership and Opens Irish Subsidiary to Support European Launch (Business Wire)
07:34AM	ImmunityBio Wins EU Nod for Bladder Cancer Combo Therapy, Stock Up (Zacks)
06:08AM	ImmunityBio (IBRX) Soars to New High on Anktiva Future Expansion (Insider Monkey)
06:03AM	ImmunityBio (IBRX) Moves 41.9% Higher: Will This Strength Last? (Zacks)
Feb-18-26 07:38PM	ImmunityBio (IBRX) Clinical Trial for Lymphona Drug Follows $505M Convertible Note Change (Insider Monkey) +41.86%
12:02PM	What's Behind The Jump In ImmunityBio Stock? (Benzinga)
09:00AM	ImmunityBio Receives Authorization from the European Commission for ANKTIVA with BCG for Non-Muscle Invasive Bladder Cancer Carcinoma in Situ, Expanding Global Access to 33 Countries (Business Wire)
Feb-17-26 11:17AM	New Treatment Modalities Are Reaching Cancers That Resisted Everything Else (PR Newswire)
09:44AM	Why Is ImmunityBio Stock Gaining Tuesday? (Benzinga)
06:07AM	ImmunityBio Reports Productive Regulatory Engagement with Saudi Food and Drug Authority at USA-Saudi Biotech Alliance Meeting Hosted by the Ministry of Investment of Saudi Arabia (Business Wire)
Feb-13-26 03:32PM	Top 10 Most Shorted Stocks: CleanSpark, Hims & Hers And More (Benzinga) -10.20%
Feb-10-26 07:42AM	ImmunityBio (IBRX) Jumps Ahead of Oncology Event (Insider Monkey) -5.34%
Feb-05-26 07:58AM	Rapid Innovation is Reshaping Oncology: Stocks in Focus (Zacks)
Feb-02-26 02:08PM	These 10 Stocks Could Be Short Squeeze Targets: Lucid, Kohl's, Avis and More (Benzinga)
09:55AM	Piper Sandler See Label Expansion Potential for ImmunityBio, Inc. (IBRX)'s ANKTIVA Following QUILT Data (Insider Monkey)
07:00AM	ImmunityBio Launches Phase 2 Chemotherapy-Free CAR-NK Cell Therapy Trial with ANKTIVA (ResQ215B) in Indolent Lymphomas (Business Wire)
Jan-30-26 02:51PM	These 10 Stocks Just Had Their Best Or Worst Month Ever - And You Might Not Know Why (Benzinga) +5.75%
Jan-28-26 10:30AM	ImmunityBio (IBRX) Sheds 4% on Profit-Taking After 14-Day Run (Insider Monkey)
09:15AM	Late-Stage Breakthroughs: How 2026's Top Clinical Platforms Are Redefining Cancer Treatment (PR Newswire)
Jan-23-26 07:00AM	ImmunityBio Reports Median Overall Survival Not Yet Reached and Lymphopenia Reversed in Recurrent Glioblastoma Patients Receiving ANKTIVA Plus CAR-NK, Chemo-Free Therapy (Business Wire) -12.13%
Jan-22-26 09:10AM	Jim Cramer on ImmunityBio: "I Really Think That You Have to Take Profits in Some of That" (Insider Monkey) +6.07%
Jan-21-26 10:46AM	ImmunityBio Stock Soars on FDA Talks for Anktiva sBLA Resubmission (Zacks) +6.79%
02:28AM	ImmunityBio (IBRX) Rockets on 12th Day, Hits Fresh High (Insider Monkey)
Jan-20-26 08:44PM	Lightning Round: Shell is 'just an ok oil company', says Jim Cramer (CNBC TV) +17.39%
01:47PM	FDA Talks Set Path For Expanded Use For ImmunityBio's Anktiva In Bladder Cancer (Benzinga)
01:19PM	ImmunityBio Extends Rally After FDA Talks (GuruFocus.com)
04:00AM	ImmunityBio Advances Regulatory Discussions with FDA on Potential Resubmission Path for ANKTIVA in BCG-Unresponsive Papillary Bladder Cancer (Business Wire)
Jan-19-26 09:15PM	ImmunityBio (IBRX) Soars 137% on Expansion Plan, Clinical Results (Insider Monkey)
05:21PM	ImmunityBio, Inc. (IBRX): A Bull Case Theory (Insider Monkey)
10:36AM	ImmunityBio Shares Surge on Updated Durable Lymphoma Study Results (Zacks)
Jan-17-26 03:09AM	ImmunityBio (IBRX) Rallies on 11th Day, Hits 52-Week High on Strong Clinical Trial Results (Insider Monkey)
Jan-16-26 02:05PM	Why ImmunityBio Stock Is Skyrocketing Again Today (Motley Fool) +39.75%
12:52PM	ImmunityBio Stock Soars On Cancer Trial Progress, FDA Timeline (Benzinga)
12:50PM	These Stocks Are Todays Movers: GE Vernova, Constellation Energy, Micron, AST SpaceMobile, Novo Nordisk, and More (Barrons.com)
11:33AM	ImmunityBio (IBRX) Extends Gains to 10th Day on 700% Anktiva Sales Jump; Time to Book Profits? (Insider Monkey)
11:04AM	ImmunityBio's 700% Revenue Boom Becomes Citadel's Latest I-Told-You-So (Benzinga)
10:41AM	Looking For A Short Squeeze? 10 Stocks Ready To Rocket (Benzinga)
09:40AM	This Biotech Stock Is Up More Than 100% This Year. Why Its Soaring Again Today. (Barrons.com)
09:27AM	Ford & BYD reportedly in talks to partner, PNC rises on earnings (Yahoo Finance Video)

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

FRCS (C)Dr. Patrick Soon-Shiong F.A.C.S.

PresidentMr. Richard Gerald Adcock

Chief Financial OfficerMr. David C. Sachs

Chief Accounting OfficerMs. Regan J. Lauer

Chief Corporate Affairs Officer & DirectorDr. Barry J. Simon M.D.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Simon Barry J.	Director	Jun 04 '26	Sale	7.18	23,033	165,306	2,827,788	Jun 05 05:29 PM
Simon Barry J.	Officer	Jun 04 '26	Proposed Sale	10.99	268,033	2,946,500		Jun 04 11:02 AM
Simon Barry J.	Director	Feb 24 '26	Sale	12.01	75,000	900,788	2,850,821	Feb 26 08:12 PM
Selecky Christobel	Director	Feb 23 '26	Option Exercise	2.98	25,000	74,500	25,000	Feb 24 08:05 PM
Selecky Christobel	Director	Feb 23 '26	Sale	10.00	25,000	250,000	0	Feb 24 08:05 PM
Sachs David C.	Chief Financial Officer	Feb 22 '26	Option Exercise	0.00	40,650	0	320,825	Feb 24 08:05 PM
SOON-SHIONG PATRICK	See remarks	Feb 22 '26	Option Exercise	0.00	114,329	0	29,816,081	Feb 24 08:05 PM
LAUER REGAN J	Chief Accounting Officer	Feb 22 '26	Option Exercise	0.00	4,065	0	117,548	Feb 24 08:05 PM
Adcock Richard	CEO & President	Feb 22 '26	Option Exercise	0.00	152,439	0	637,904	Feb 24 08:04 PM
Simon Barry J.	Director	Feb 22 '26	Option Exercise	0.00	15,243	0	3,096,847	Feb 24 08:03 PM
Simon Barry J.	Director	Feb 23 '26	Sale	10.25	165,000	1,691,102	2,925,821	Feb 24 08:03 PM
Simon Barry J.	Director	Feb 20 '26	Sale	9.25	10,000	92,500	3,081,604	Feb 24 08:03 PM
CHRISTOBEL SELECKY	Director	Feb 23 '26	Proposed Sale	8.70	25,000	217,500		Feb 23 04:28 PM
SOON-SHIONG PATRICK	See remarks	Feb 10 '26	Option Exercise	0.00	274,122	0	29,820,312	Feb 12 09:29 PM
Sachs David C.	Chief Financial Officer	Feb 10 '26	Option Exercise	0.00	82,236	0	322,818	Feb 12 08:50 PM
LAUER REGAN J	Chief Accounting Officer	Feb 10 '26	Option Exercise	0.00	5,482	0	115,740	Feb 12 08:50 PM
Adcock Richard	CEO & President	Feb 10 '26	Option Exercise	0.00	274,122	0	625,513	Feb 12 08:50 PM
Simon Barry J.	Director	Jan 20 '26	Sale	7.20	151,967	1,094,297	3,091,604	Jan 21 08:34 PM
Selecky Christobel	Director	Jan 16 '26	Option Exercise	2.98	50,000	149,000	50,000	Jan 21 08:33 PM
Selecky Christobel	Director	Jan 20 '26	Option Exercise	2.98	25,000	74,500	25,000	Jan 21 08:33 PM
Selecky Christobel	Director	Jan 16 '26	Sale	5.00	50,000	250,000	0	Jan 21 08:33 PM
Selecky Christobel	Director	Jan 20 '26	Sale	7.51	25,000	187,650	0	Jan 21 08:33 PM
CHRISTOBEL SELECKY	Director	Jan 20 '26	Proposed Sale	5.52	25,000	138,000		Jan 20 04:29 PM
Simon Barry J.	Officer	Jan 20 '26	Proposed Sale	10.33	571,967	5,909,546		Jan 20 11:05 AM
CHRISTOBEL SELECKY	Director	Jan 16 '26	Proposed Sale	3.95	50,000	197,500		Jan 16 04:22 PM
Sachs David C.	Chief Financial Officer	Dec 31 '25	Option Exercise	0.00	30,397	0	256,017	Jan 05 06:11 PM
Adcock Richard	CEO & President	Dec 31 '25	Option Exercise	0.00	34,483	0	368,901	Jan 05 06:10 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

IBRX

ImmunityBio Inc

Upgrade your Finviz experience